A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer : NSGO AVANOVA1/ENGOT-OV24

M.R. Mirza; T.K. Bergmann; M. Mau-Sørensen; R.D. Christensen; E. Åvall-Lundqvist; M.J. Birrer; M. Jørgensen; H. Roed; S. Malander; F. Nielsen; U. Lassen; K. Brøsen; L. Bjørge; J. Mäenpää

doi:10.1007/s00280-019-03917-z

A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer : NSGO AVANOVA1/ENGOT-OV24

M.R. Mirza
, T.K. Bergmann
, M. Mau-Sørensen
, R.D. Christensen
, E. Åvall-Lundqvist
, M.J. Birrer
, M. Jørgensen
, H. Roed
, S. Malander
, F. Nielsen
, U. Lassen
, K. Brøsen
, L. Bjørge
, J. Mäenpää

Research output: Contribution to journal › Article › Scientific › peer-review

27 Citations (Scopus)

Original language	English
Pages (from-to)	791-798
Journal	Cancer Chemotherapy and Pharmacology
Volume	84
Issue number	4
DOIs	https://doi.org/10.1007/s00280-019-03917-z
Publication status	Published - 2019
Publication type	A1 Journal article-refereed

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

BRCA
Bevacizumab
Niraparib
Ovarian cancer
PARP inhibitor

Publication forum classification

Publication forum level 1

Access to Document

10.1007/s00280-019-03917-z

Cite this

Mirza, M. R., Bergmann, T. K., Mau-Sørensen, M., Christensen, R. D., Åvall-Lundqvist, E., Birrer, M. J., Jørgensen, M., Roed, H., Malander, S., Nielsen, F., Lassen, U., Brøsen, K., Bjørge, L., & Mäenpää, J. (2019). A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer : NSGO AVANOVA1/ENGOT-OV24. Cancer Chemotherapy and Pharmacology, 84(4), 791-798. https://doi.org/10.1007/s00280-019-03917-z

@article{7c8d0c68ec244ea584a8df12d2fa617f,

title = "A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer : NSGO AVANOVA1/ENGOT-OV24",

keywords = "BRCA, Bevacizumab, Niraparib, Ovarian cancer, PARP inhibitor, BRCA, Bevacizumab, Niraparib, Ovarian cancer, PARP inhibitor",

author = "M.R. Mirza and T.K. Bergmann and M. Mau-S{\o}rensen and R.D. Christensen and E. {\AA}vall-Lundqvist and M.J. Birrer and M. J{\o}rgensen and H. Roed and S. Malander and F. Nielsen and U. Lassen and K. Br{\o}sen and L. Bj{\o}rge and J. M{\"a}enp{\"a}{\"a}",

year = "2019",

doi = "10.1007/s00280-019-03917-z",

language = "English",

volume = "84",

pages = "791--798",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer",

number = "4",

}

Mirza, MR, Bergmann, TK, Mau-Sørensen, M, Christensen, RD, Åvall-Lundqvist, E, Birrer, MJ, Jørgensen, M, Roed, H, Malander, S, Nielsen, F, Lassen, U, Brøsen, K, Bjørge, L & Mäenpää, J 2019, 'A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer : NSGO AVANOVA1/ENGOT-OV24', Cancer Chemotherapy and Pharmacology, vol. 84, no. 4, pp. 791-798. https://doi.org/10.1007/s00280-019-03917-z

A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer : NSGO AVANOVA1/ENGOT-OV24. / Mirza, M.R.; Bergmann, T.K.; Mau-Sørensen, M. et al.
In: Cancer Chemotherapy and Pharmacology, Vol. 84, No. 4, 2019, p. 791-798.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer : NSGO AVANOVA1/ENGOT-OV24

AU - Mirza, M.R.

AU - Bergmann, T.K.

AU - Mau-Sørensen, M.

AU - Christensen, R.D.

AU - Åvall-Lundqvist, E.

AU - Birrer, M.J.

AU - Jørgensen, M.

AU - Roed, H.

AU - Malander, S.

AU - Nielsen, F.

AU - Lassen, U.

AU - Brøsen, K.

AU - Bjørge, L.

AU - Mäenpää, J.

PY - 2019

Y1 - 2019

KW - BRCA

KW - Bevacizumab

KW - Niraparib

KW - Ovarian cancer

KW - PARP inhibitor

KW - BRCA

KW - Bevacizumab

KW - Niraparib

KW - Ovarian cancer

KW - PARP inhibitor

U2 - 10.1007/s00280-019-03917-z

DO - 10.1007/s00280-019-03917-z

M3 - Article

SN - 0344-5704

VL - 84

SP - 791

EP - 798

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 4

ER -